Medimix Announces ScanBuzz™: The First Social Media Monitoring Platform for the Pharmaceutical, Medical Device and Biotechnology Industries.
Miami (November 16, 2009) Medimix International (www.medimix.net) has developed and is announcing the launch of ScanBuzz™, the first platform for life sciences companies to monitor online mentions of their brands and products in the social networking arena. With the increased number of physicians and patients sharing their experiences online, Scanbuzz™ allows the industry to discover, listen, and manage feedback and develop relations with social network users.
From forums to blogs, social networks to multimedia sharing websites, Twitter to YouTube, and more, ScanBuzz™ uncovers online conversations and gives companies the tools to track, analyze, manage, monitor, and report on their social media engagement activities.
As more users openly discuss drugs and healthcare issues, social media increasingly affects all the processes within the enterprise, including marketing, public relations, customer support, product development, competitive intelligence, as well as legal and medical. ScanBuzz™ helps pharmaceutical companies discover and listen to what healthcare professionals and patients are saying about them and to act on these mentions.
With Scanbuzz™, Medimix International currently tracks the top 200 pharmaceutical products and 100 corporate brands. Brands are tracked in a variety of therapeutic areas from oncology to respiratory, to CNS, diabetes and endocrinology. Clients can also monitor their own choice of brands, disease or conditions, therapeutic areas, or any concept they are interested in.
Recently, Medimix International conducted a survey on the use of social networking websites among healthcare professionals; over 500 oncologists, hematologists, cardiologists and general practitioners in Europe, US and Latin America were interviewed. The study revealed more than one-third (34%) declared they use social networks.
“For the first time ever, drug manufacturers have the opportunity to monitor the word-of-mouth happening among patients, or between patients and healthcare professionals. Customers are now more vocal and accessible than ever before, and life sciences companies must address the new expectations and needs of the social physician and patient. ScanBuzz™ equips pharmaceutical teams with essential social media listening, management and reporting capabilities,” says Henry Gazay, CEO of Medimix international.
For example, Scanbuzz™ uncovered that the amount of online discussions on a particular oncology product increased by five-fold during the ESMO conference last September, which gave the manufacturer of the drug an immediate indication of their Return on Investment (ROI) at this congress. Also, on the day the Pfizer-Wyeth merger became effective (October 15th 2009), Scanbuzz™ recorded a four-fold surge in buzz about Wyeth, with patients and employees tweeting their concerns about the merger, and financial traders blogging about the impact it would have on the short to mid-term value of Pfizer’s stock.
“With Scanbuzz™ drug manufacturers are able to provide new levels of satisfaction and service by listening to their customers online and responding to them. They can also set alerts to help them anticipate competitors’ moves, prevent crises and track rumors,” remarks Alex de Carvalho, Social Media Director at Medimix International, and co-developer of Scanbuzz™.
The ScanBuzz™ platform provides Life Sciences companies with the following:
• Marketing teams have access to more pertinent information about their customers through their online discussions
• Marketing Research departments can monitor daily the number of comments posted about their brands or their competitors in blogs, forums and social networking sites
• Sales teams can identify and meet prospective, influential physicians, reducing the overall cost of qualified leads
• Medical support teams can proactively respond to patients, based on a better understanding of their issues
• Public relations, advertising and communications teams understand new contexts for their outreach activities
• Community management teams can measure and evaluate the types of social media platforms and communities that are most effective in generating influential word-of-mouth.
Scanbuzz™ is available through a small monthly subscription fee, based on the number of simultaneous users and the number of brands tracked.
• Investors can anticipate the impact of recent news such as results of clinical trials or announcements of M&A.
For more information about ScanBuzz's capabilities contact Kathryn McAdam, Executive Communications at Medimix International : kmcadam@medimix.net
To request a demo contact your local representative, listed below.
About Medimix International
Medimix International is a dynamic provider of advanced marketing research solutions for the healthcare industry worldwide. Medimix’s proprietary panel provides direct access to over 500,000 physicians and healthcare professionals from around the world.
Learn more at www.medimix.net.
Communications :
Medimix International
Kathryn McAdam
Executive communications
kmcadam@medimix.net
+1 305-573-5233
Sales Representatives:
USA
Medimix International
Frank Vezzuto
Director Business Development - US
fvezzuto@medimix.net
+1 973 845 4377
Europe
Medimix Europe
Paul Taylor
Director of Business Development - Europe
ptaylor@medimix.net
+44 207 847 4019
Asia
Medimix Asia
Bruno Leraillez
Partner
bleraillez@medimix.net
+852 2824 8222
Latin America
Medimix LatAm
Martha Dias
Director LatAm
mdias@medimix.net
+55 11 34437721